Prognosis
Bristol-Myers Patent Win Over Gilead Grows to $1.2 Billion
- Enhanced damages, pre-judgment interest added to jury award
- Fight is over Kite drug Yescarta, pioneering cancer treatment
This article is for subscribers only.
Bristol-Myers Squibb Co. persuaded a judge to boost damages to $1.2 billion in its patent-infringement case against Gilead Sciences Inc.’s Kite unit over revolutionary treatments that use a body’s own immune system to fight cancer.
Gilead owes Bristol-Myers enhanced damages of $389 million and pre-judgment interest of $33 million, on top of more than $778 million awarded in December by a federal jury, U.S. District Judge Philip S. Gutierrez ruled.